


Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

VBLT:034US

Serial No.

10/824,771

Applicant

Jackie D. Corbin

Sharron H. Francis

Filing Date:

April 15, 2004

Group:

Unknown

1651

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Ballard <i>et al.</i> , "Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotied phosphodiesterase isozymes," <i>J. Urol.</i> , 159:2164-2171, 1998.
	C2	Corbin <i>et al.</i> , "Phosphorylation of phosphodiesterase-5 by cyclic meucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities," <i>Eur. J. Biochem.</i> , 267:2760-2767, 2000.
	C3	Corbin <i>et al.</i> , "[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP," <i>Mol. Pharmacol.</i> , 63(6):1364-1372, 2003.
	C4	Corbin and Francis, "Cyclic GMP phosphodiesterase-5: target of sildenafil," <i>J. Biol. Chem.</i> , 274(20):13729-13732, 1999.
	C5	Francis <i>et al.</i> , "Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity," <i>J. Biol. Chem.</i> , 277(49):47581-47587, 2002.
	C6	Francis <i>et al.</i> , "Single step isolation of sildenafil from commercially available Viagra tablets," <i>Int. J. Impot. Res.</i> , 15(5):369-372, 2003.
	C7	Gopal <i>et al.</i> , "Allosteric sites of phosphodiesterase-5 (PDE5): a potential role in negative feedback regulationo f cGMP signaling in corpus cavernosum," <i>Eur. J. Biochem.</i> , 268:3304-3312, 2001.

25416784.1

EXAMINER:

DATE CONSIDERED:

08/25/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. VBLT:034US	Serial No. 10/824,771
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Jackie D. Corbin Sharron H. Francis	
		Filing Date: April 15, 2004	Group: Unknown <i>1657</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>Yell</i>	C8	Okada and Asakawa, "Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP," <i>Biochemistry</i> , 41:9672-9679, 2002.
<i>WJL</i>	C9	Saenz de Tajada <i>et al.</i> , "The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil," <i>Int. J. Impot. Res.</i> , 13(5):282-290, 2001.
<i>WJL</i>	C10	Turko <i>et al.</i> , "Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds," <i>Mol. Pharmacol.</i> , 56:124-130, 1999.

25416784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.